GPX Medical (GPXMED.ST) Stock Analysis & AI Equity Report
GPX Medical (GPXMED.ST) overview
GPX Medical (GPXMED.ST) stock analysis and AI equity research. For the latest completed financial year, 2021, GPX Medical reported revenue of SEK 0.6m and operating profit of SEK -6.7m; the year-end share price was N/A and market capitalisation was N/A. GPX Medical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get GPX Medical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About GPX Medical
GPX Medical AB develops and commercializes NEOLA, a medical device for continuous lung monitoring of preterm infants in neonatal intensive care. The company’s business is built around improving respiratory monitoring through its patented technology, with revenue potential tied to product sales, clinical adoption, and related commercialization efforts in neonatal care markets.
Generate the GPX Medical report
GPX Medical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for GPX Medical and represent the latest completed financial year (2021). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.